These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia]. Bajnok L Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322 [TBL] [Abstract][Full Text] [Related]
3. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
4. Nonstatin therapies for management of dyslipidemia: a review. Sando KR; Knight M Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of and treatment options for increased lipoprotein(a)]. Zsíros N; Paragh G; Harangi M Orv Hetil; 2014 Apr; 155(16):607-14. PubMed ID: 24733102 [TBL] [Abstract][Full Text] [Related]
11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
12. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. Jacobson TA Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969 [TBL] [Abstract][Full Text] [Related]
13. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future. Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033 [TBL] [Abstract][Full Text] [Related]